全文获取类型
收费全文 | 253篇 |
免费 | 6篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 5篇 |
妇产科学 | 2篇 |
基础医学 | 22篇 |
口腔科学 | 7篇 |
临床医学 | 14篇 |
内科学 | 57篇 |
皮肤病学 | 1篇 |
神经病学 | 2篇 |
特种医学 | 6篇 |
外科学 | 37篇 |
综合类 | 2篇 |
预防医学 | 4篇 |
药学 | 12篇 |
肿瘤学 | 85篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 6篇 |
2019年 | 3篇 |
2018年 | 14篇 |
2017年 | 3篇 |
2016年 | 1篇 |
2015年 | 5篇 |
2014年 | 7篇 |
2013年 | 13篇 |
2012年 | 15篇 |
2011年 | 13篇 |
2010年 | 7篇 |
2009年 | 10篇 |
2008年 | 15篇 |
2007年 | 7篇 |
2006年 | 9篇 |
2005年 | 14篇 |
2004年 | 10篇 |
2003年 | 13篇 |
2002年 | 10篇 |
2001年 | 10篇 |
2000年 | 10篇 |
1999年 | 5篇 |
1998年 | 4篇 |
1997年 | 1篇 |
1996年 | 3篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1992年 | 3篇 |
1991年 | 6篇 |
1990年 | 3篇 |
1989年 | 8篇 |
1988年 | 4篇 |
1987年 | 4篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有259条查询结果,搜索用时 15 毫秒
61.
Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. 总被引:7,自引:3,他引:7
S Siena M Bregni B Brando N Belli F Ravagnani L Gandola A C Stern P M Lansdorp G Bonadonna A M Gianni 《Blood》1991,77(2):400-409
Optimum methods of harvesting circulating hematopoietic progenitors for autologous transplantation to support myeloablative cancer therapy are still uncertain, mostly because of the lack of an assay for marrow-repopulating stem cells. The CFU-GM assay, the commonly used indirect indicator of the quality of the graft, is poorly standardized and provides results evaluable only retrospectively. Based on the knowledge that hematopoietic progenitors express CD34 and CD33 differentiation antigens, we developed a dual-color direct immunofluorescence flow cytometry assay with the aim of replacing the CFU-GM assay advantageously. For this purpose, we applied both assays to 157 blood samples obtained daily throughout 20 different recoveries from pancytopenia induced by high-dose cyclophosphamide or etoposide cancer therapy with or without recombinant human GM colony-stimulating factor (rhGM-CSF). The appearance of CD34+ cells in the circulation indicated that hematopoietic progenitors had increased to more than 500 CFU-GM/mL, a level clinically adequate for large-scale harvest by leukapheresis. Total CD34+ cells correlated well with CFU-GM (r = .89), and data could be fitted by a linear regression line described by the equation y = 388.3 + 64.0x, where y = CFU-GM/mL and x = CD34+ cells per microliter. Moreover, in a series of six patients treated with myeloablative chemoradiotherapy, early hematopoietic recovery of marrow functions was predicted more accurately by the number of transplanted CD34+/CD33+ cells than by either total nucleated cells, CFU-GM, CD34+/CD33- cells, or CD34-/CD33+ cells. Data presented in this article favor clinical use of the CD34/CD33 flow cytometry assay to guide harvesting of circulating hematopoietic progenitors for autologous transplantation and contribute to better understanding of the role played by circulating hematopoietic progenitor cell subsets in marrow recovery after myeloablative cancer therapy. 相似文献
62.
63.
Andrea Minervini Giampaolo Siena Lorenzo Masieri Alberto Lapini Sergio Serni Marco Carini 《Surgical endoscopy》2009,23(8):1831-1834
Background This study aimed to evaluate the authors’ initial experience with antegrade stenting. It focused on the success rate, time
required for stent insertion, possible complications, and relative solutions in the first 44 procedures.
Methods Between March 2005 and April 2008, 44 patients (21 women and 23 men) with a mean age of 33 years (range, 17–59 years) underwent
transperitoneal laparoscopic Anderson–Hynes pyeloplasty in the authors’ department. Antegrade stenting was attempted for all
the patients. The time required for stent insertion was recorded as the time from cannula insertion to the correct positioning
of the stent in the pelvis. A 4.8-Fr, 26-cm stent was the stent of choice for the first four cases. Then the 6-Fr, 26-cm stent
was adopted for all the remaining patients except for one, for whom a 6-Fr, 28-cm stent was adopted.
Results The mean operative time was 197 min (median, 180 min; range, 150–390 min). No conversions to open surgery were required. The
stent was positioned correctly in the bladder at the end of the antegrade procedure in 97.7% of the patients without the need
for a postoperative X-ray in 95% of the cases. The mean time required for antegrade insertion of the stent was 7 min 30 s
(median, 6 min 13 s; range, 3 min 40 s to 22 min 30 s). In the final 12 procedures, the time for stent insertion was constantly
reduced to a mean of 4 min 10 s (median, 4 min; range, 3 min 40 s to 7 min). Neither intraoperative nor postoperative complications
related to antegrade stent positioning were observed.
Conclusion Our data confirm the antegrade procedure to be an easy-to-learn, safe, and reliable stenting technique, with an overall mean
time of 7 min 30 s required for insertion, and with a mean time of 4 min 10 s required for insertion in the final 12 procedures.
It obviates the problem of having the stent in the renal pelvis during dissection and suturing and of repositioning the patient
onto the flank for the laparoscopic procedure. 相似文献
64.
Giorgio Vittorio Scagliotti Vera Hirsh Salvatore Siena David H. Henry Penella J. Woll Christian Manegold Philippe Solal-Celigny Gladys Rodriguez Maciej Krzakowski Nilesh D. Mehta Lara Lipton José Angel García-Sáenz José Rodrigues Pereira Kumar Prabhash Tudor-Eliade Ciuleanu Vladimir Kanarev Huei Wang Arun Balakumaran Ira Jacobs 《Journal of thoracic oncology》2012,7(12):1823-1829
65.
Alessio Amatu Andrea Sartore-Bianchi Katia Bencardino Andrea Cassingena Filippo Venturini Felicia Giacobbe Lisa Pietrogiovanna Giovanna Marrapese Alessandra Gambaro Alessandro Belotti Salvatore Siena 《Current colorectal cancer reports》2012,8(4):272-276
The introduction into clinical practice of KRAS mutational status for selection of patients has dramatically improved the results from use of anti-EGFR monoclonal antibodies cetuximab or panitumumab for metastatic colorectal cancer. More refined selection of patients by means of other molecular alterations, for example BRAF, PIK3CA, and NRAS has enabled further increases in responses to first-line and other therapy for metastatic disease. Elucidation of differences among specific subtypes of KRAS mutations affecting sensitivity, and identification of other mechanisms by which tumor cell resistance is acquired, revealing ??druggable?? molecular targets to overcome resistance, are clearly a priority of clinical research. Recent data have revealed potentially different activity of the G13D KRAS mutation in conferring resistance to cetuximab. This review examines the most recent evidence available on codon 13 mutation in metastatic colorectal cancer, including both preclinical and available clinical data, indicating differences between codon 13 and other KRAS mutations and analyzing its prognostic and predictive use in EGFR-targeted therapy. 相似文献
66.
67.
S Cascinu F Graziano F Ferraù V Catalano C Massacesi D Santini R R Silva S Barni A Zaniboni N Battelli S Siena P Giordani D Mari A M Baldelli S Antognoli R Maisano D Priolo M A Pessi G Tonini S Rota R Labianca 《Annals of oncology》2002,13(5):716-720
BACKGROUND: To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination (TOMOX) as first-line chemotherapy for patients with advanced colorectal cancer. MATERIALS AND METHODS: Previously untreated patients with metastatic colorectal cancer received raltitrexed 3 mg/m2 plus oxaliplatin 100 mg/m2, both intravenously, on day 1 every 3 weeks. Patients were re-evaluated after every third cycle and chemotherapy was continued up to tolerance or disease progression. RESULTS: Fifty-eight patients from 13 Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD) centers were accrued from September 1999 to November 2000. According to the intention-to-treat analysis from 58 patients, the overall response rate was 50% [95% confidence interval (CI) 38% to 62%], with three complete responses and 26 partial responses. The median overall survival (44 patients currently alive) was >9 months and the median time to disease progression was 6.5 months (range 1-15 months). The main hematological toxicity was grade III/IV neutropenia, which occurred in 17% of patients, while anemia and thrombocytopenia were uncommon. Grade III/IV non-hematological toxicities were transient transaminitis (17% of patients); asthenia (16% of patients); neurotoxicity (10% of patients) and diarrhea (7% of patients). No toxic death was observed, one patient with grade IV asthenia after the first cycle refused chemotherapy. CONCLUSIONS: The results of this study suggest that the TOMOX combination is an effective and well tolerated regimen for the treatment of advanced colorectal cancer. Its ease of administration and patient tolerance warrant further investigation as an alternative to fluoropyrimidine-based regimens with repeated and prolonged fluorouracil infusions. 相似文献
68.
69.
Pace E Siena L Ferraro M Profita M Mondello P Chiappara G Montalbano AM Giarratano A Bonsignore G Gjomarkaj M 《European journal of cancer (Oxford, England : 1990)》2006,42(14):2382-2389
The recurrence of pleural effusions is a common event in a variety of neoplastic diseases. The objective of this study was to identify the mechanisms promoting the homing and growth of cancer cells within the pleural space. A cancer cell line recovered from malignant pleural fluids (lung adenocarcinoma cell line) that constitutively expresses cyclooxygenase 2 (COX-2) and all types of prostaglandin receptors was studied. It was first demonstrated using a matrigel system, that malignant pleural fluids increase the invasiveness of adenocarcinoma cells more than congestive heart failure (CHF) pleural fluids. Moreover, exposure to exudative malignant, but not to CHF pleural fluids, increased the mRNA (measured by real-time polymerase chain reaction (PCR)) and protein expression of COX-2 (measured by Western blot), as well as the activation and nuclear translocation of nuclear factor kappaB (NFkappaB) in cancer cells. These events are all actively regulated by prostaglandin E2 (PGE2), since the addition of synthetic PGE2 to cancer cells and the depletion of PGE2 from malignant pleural fluids or the inhibition of COX-2 activity significantly increased and reduced these phenomena, respectively. Moreover, malignant pleural effusions and synthetic PGE2 increased the long-term proliferation of cancer cells and reverted the impairment in long-term proliferation due to talc exposure. This study demonstrates that PGE2 present in malignant effusions contributes to cancer expansion and may protect cancer cells by anti-proliferative effects induced by talc. 相似文献
70.
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. 总被引:1,自引:0,他引:1
Patrizia Comoli Paolo Pedrazzoli Rita Maccario Sabrina Basso Ornella Carminati Massimo Labirio Roberta Schiavo Simona Secondino Chiara Frasson Cesare Perotti Mauro Moroni Franco Locatelli Salvatore Siena 《Journal of clinical oncology》2005,23(35):8942-8949
PURPOSE: Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-related malignancy expressing EBV antigens that are possible targets of cell therapy, including latent membrane protein 2 (LMP2). We conducted a clinical trial of EBV-targeted cell therapy with autologous virus-specific cytotoxic T lymphocytes (CTLs) for NPC refractory to conventional treatments. PATIENTS AND METHODS: Ten patients with EBV-related stage IV NPC in progression after conventional radiotherapy and chemotherapy received intravenously autologous EBV-specific CTLs reactivated and expanded ex vivo from peripheral blood lymphocytes through stimulation with EBV-transformed autologous B-lymphoblastoid cell lines (LCL). Toxicity, specific cellular immune responses, and clinical tumor responses were evaluated. RESULTS: EBV-specific CTLs could be generated in all patients and were predominantly CD3+/CD8+ T lymphocytes displaying specific killing of autologous EBV-LCL, autologous NPC cells as well as autologous targets bearing the EBV antigen LMP2. Patients received two to 23 infusions of EBV-specific CTLs that were well tolerated with the exception of grade 1 to 2 inflammatory reactions at the tumor site in two cases. Control of disease progression was obtained in six of 10 patients (two with partial response and four with stable disease). Analysis of interferon-gamma-producing cells demonstrated an increased frequency of EBV-specific immunity, with appearance of LMP2-specific responses in four patients, of whom three had clinical benefit. CONCLUSION: Cell therapy with EBV-targeted autologous CTLs is safe, induces LMP-2-specific immunologic responses, and is associated with objective responses and control of disease progression in patients with stage IV NPC resistant to conventional treatments. 相似文献